Advancing evidence to enable optimal communicable disease control
Catherine M. Bennett A B * Meru Sheel C DA
B
C
D
Abstract
The COVID-19 pandemic brought epidemiology into public focus globally. Understanding patterns and determinants of disease spread was central to risk assessment and the modelling of drivers of transmission to forecast outcomes under different intervention scenarios. Epidemiological analytics, including the reproduction number, were being discussed by the media and the public in ways epidemiologists and biostatisticians could not have foreseen. Yet the statistics being reported were largely confined to two ends of the evidence spectrum – at one end, raw case counts, hospitalisations and deaths, and at the other, sophisticated statistical modelling based on disease dynamics averaged at the whole-of-population level. Other core epidemiological analytic methods that add a more nuanced understanding of variation in disease transmission within and across populations, and risk of infection, were underrepresented. In Australia, for example, the purposeful collection of data to estimate subpopulation-specific case rates, generate relative risks across subpopulations and allow meaningful interpretation within and across populations was limited. This also hampered the real-world evaluation of specific health interventions, including vaccination, and the generation of updated population-specific estimates for statistical model parameters. This was a global phenomenon, though some countries did better than others. What was fundamentally missing was a clear investment in, and coordinated approach to, the quality of surveillance data needed for (a) tracking disease transmission and the degree of control achieved, both of which changed over time, and (b) public communication. The independent inquiry into the Australian Government's COVID-19 Response had evidence generation as a central theme, and investment in evidence synthesis capability and data sharing as clear recommendations for the way forward. The importance of evidence was also raised in discussions informing the draft global Pandemic Agreement. This remains a worrying gap in pandemic readiness, including in well-resourced countries such as Australia where the nuance in public health policy was constrained by the reliance on basic descriptive epidemiology, urban-focused population-level modelling and data insights imported from other countries.
Keywords: analysis, data linkage, epidemiology, evaluation, infectious disease, outbreaks, pandemics, policy, surveillance.
References
1 Brownson RC, Gurney JG, Land GH. Evidence-based decision making in public health. J Public Health Manag Pract 1999; 5: 86-97.
| Crossref | Google Scholar | PubMed |
2 Editorial.. How epidemiology has shaped the COVID pandemic. Nature 2021; 589: 491-2.
| Crossref | Google Scholar | PubMed |
3 Brown RB. Biases in COVID-19 Case and Death Definitions: Potential Causes and Consequences. Disaster Medicine and Public Health Preparedness 2022; 17: e313.
| Crossref | Google Scholar |
4 Brown RB. Biases in COVID-19 Case and Death Definitions: Potential Causes and Consequences. Disaster Med Public Health Prep 2022; 17: e313.
| Crossref | Google Scholar | PubMed |
5 Eisinger-Mathason TSK, Leshin J, Lahoti V, Fridsma DB, Mucaj V, Kho AN. Data linkage multiplies research insights across diverse healthcare sectors. Commun Med 2025; 5: 58.
| Crossref | Google Scholar | PubMed |
6 Field E, Strathearn M, Boyd-Skinner C, Dyda A. Usefulness of linked data for infectious disease events: a systematic review. Epidemiol Infect 2023; 151: e46.
| Crossref | Google Scholar | PubMed |
7 Dang A. Real-World Evidence: A Primer. Pharmaceut Med 2023; 37: 25-36.
| Crossref | Google Scholar | PubMed |
8 Rinette B, Kierste M, Chris P, Ben O, Nicole S, Benjamin A, Tanya P, Christopher N, Partrick S, Cathine L, Nita M. Challenges in reported COVID-19 data: best practices and recommendations for future epidemics. BMJ Global Health 2021; 6: e005542.
| Google Scholar |
9 Tan SY, Foo C, Verma M, Hanvoravongchai P, Cheh PLJ, Pholpark A, Marthias T, Hafidz F, Prawidya Putri L, Mahendradhata Y, Giang KB, Nachuk S, Wang H, Lim J, Legido-Quigley H. Mitigating the impacts of the COVID-19 pandemic on vulnerable populations: Lessons for improving health and social equity. Soc Sci Med 2023; 328: 116007.
| Crossref | Google Scholar | PubMed |
10 Chen J, Lu H, Melino G, Boccia S, Piacentini M, Ricciardi W, Wang Y, Shi Y, Zhu T. COVID-19 infection: the China and Italy perspectives. Cell Death & Disease 2020; 11(6): 438.
| Crossref | Google Scholar |
11 Koh D. Migrant workers and COVID-19. Occup Environ Med 2020; 77: 634-6.
| Crossref | Google Scholar | PubMed |
12 Australian Bureau of Statistics. COVID-19 Mortality in Australia: Deaths registered to 28 February 2022. 2022. Available at https://www.abs.gov.au/articles/covid-19-mortality-australia-deaths-registered-28-february-2022 [cited 19 April 2025].
13 Leask J, Christou-Ergos M, Abdi I, Mboussou F, Sabahelzain MM, Wiley KE, Lambach P, Sim SY. Informing the development of transmission modelling guidance for global immunization decision-making: A qualitative needs assessment. Vaccine 2025; 49: 126800.
| Crossref | Google Scholar | PubMed |
14 Doherty Institute. Modelling. Melbourne; 2025. Available at https://www.doherty.edu.au/our-work/institute-themes/viral-infectious-diseases/covid-19/covid-19-modelling/modelling [cited 4 June 2025]
15 How modelling can better support public health policy making: the Lancet Commission on Strengthening the Use of Epidemiological Modelling of Emerging and Pandemic Infectious Diseases. Lancet 2024; 403(10429): 789-791.
| Crossref | Google Scholar |
16 University of Cape Town. Modelling and Simulation Hub, Africa. 2025. Available at https://science.uct.ac.za/masha [cited 4 June 2025].
17 National Disease Modelling Consortium. Mumbai: NDMC; 2025. Available at https://www.ndmconsortium.com/ [cited 4 June 2025].
18 ACEFA. Australia-Aotearoa Consortium for Epidemic Forecasting & Analytics. 2024. Available at https://acefa-hubs.github.io/ [cited 4 June 2025].
19 WHO. International Health Regulations: amendments: Questions and answers. Geneva: WHO; 2024. Available at https://www.who.int/news-room/questions-and-answers/item/international-health-regulations-amendments [cited 4 June 2025].
20 WHO. International Health Regulations (2005) – A/77/A/CONF./14. In: World Health Organization, editor. 2024. Available at https://apps.who.int/gb/ebwha/pdf_files/WHA77/A77_ACONF14-en.pdf [cited 4 June 2025].
21 WHO. World Health Assembly adopts historic Pandemic Agreement to make the world more equitable and safer from future pandemics. News release. Geneva, Switzerland: WHO; 2025. Available at https://www.who.int/news/item/20-05-2025-world-health-assembly-adopts-historic-pandemic-agreement-to-make-the-world-more-equitable-and-safer-from-future-pandemics [cited 4 June 2025].
22 WHO. Proposal for negotiating text of the WHO Pandemic Agreement. 30 October 2023. Available at https://apps.who.int/gb/inb/pdf_files/inb7/A_INB7_3-en.pdf [cited 23 May 2025].
23 WHO. Proposal for the WHO Pandemic Agreement 27 May 2024. In: World Health Organization, editor. 2024. Available at https://apps.who.int/gb/ebwha/pdf_files/WHA77/A77_10-en.pdf [cited 4 June 2025].
24 WHO. The first 100 days of the COVID-19 response: past investments in health security system pay off, and learning lessons for the future. World Health Organization; 2020. Available at https://www.who.int/cambodia/news/feature-stories/detail/the-first-100-days-of-the-covid-19-response-past-investments-in-health-security-system-pay-off-and-learning-lessons-for-the-future [cited 23 May 2025].
25 Marcato AJ, Black AJ, Walker CR, Morris D, Meagher N, Price DJ, McVernon J. Learnings from the Australian first few X household transmission project for COVID-19. Lancet Reg Health West Pac 2022; 28: 100573.
| Crossref | Google Scholar | PubMed |
26 Clemens J, Aziz AB, Tadesse BT, Kang S, Marks F, Kim J. Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries. eClinicalMedicine 2022; 43: 101253.
| Crossref | Google Scholar | PubMed |
27 WHO. Strengthening the global architecture for health emergency prevention, preparedness, response and resilience. In: World Health Organization, editor. 2023. Available at https://www.who.int/publications/m/item/strengthening-the-global-architecture-for-health-emergency-prevention--preparedness--response-and-resilience [cited 23 May 2025].
28 Morris JS. Tracking vaccine effectiveness in an evolving pandemic, countering misleading hot takes and epidemiologic fallacies. Am J Epidemiol 2025; 194: 898-907.
| Crossref | Google Scholar | PubMed |
29 Office for National Statistics. Evaluation of the ONS’ role in the COVID-19 Infection Surveillance Programme. 2021. Available at https://www.ons.gov.uk/aboutus/transparencyandgovernance/onsevaluationstrategy/onsevaluation/evaluationoftheonsroleinthecovid19infectionsurveillanceprogramme [cited 18 April 2025].
30 Simpson CR, Robertson C, Vasileiou E, McMenamin J, Gunson R, Ritchie LD, Woolhouse M, Morrice L, Kelly D, Stagg HR, Marques D, Murray J, Sheikh A. Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data. BMJ Open 2020; 10: e039097.
| Crossref | Google Scholar | PubMed |
31 Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. N Engl J Med 2021; 385: 2195-7.
| Crossref | Google Scholar | PubMed |
32 Bollaerts K, Wyndham-Thomas C, Miller E, Izurieta HS, Black S, Andrews N, Rubbrecht M, Van Heuverswyn F, Neels P. The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment- a meeting report. Biologicals 2024; 85: 101750.
| Crossref | Google Scholar | PubMed |
33 Department of the Prime Minister and Cabinet. COVID-19 Response Inquiry Report. 2024. Available at https://www.pmc.gov.au/node/5225 [cited 23 May 2025].
34 Rawson T, Brewer T, Veltcheva D, Huntingford C, Bonsall MB. How and When to End the COVID-19 Lockdown: An Optimization Approach. Front Public Health 2020; 8: 262.
| Crossref | Google Scholar | PubMed |
35 Basseal JM, Bennett CM, Collignon P, Currie BJ, Durrheim DN, Leask J, McBryde ES, McIntyre P, Russell FM, Smith DW, Sorrell TC, Marais BJ. Key lessons from the COVID-19 public health response in Australia. Lancet Reg Health West Pac 2023; 30: 100616.
| Crossref | Google Scholar | PubMed |
36 Tippett E, Hitch D, Irving L, Watters D. Post-acute COVID-19 condition (PACC): a perspective on collaborative Australian research imperatives and primary health models of care. Aust J Prim Health 2023; 29: 293-5.
| Crossref | Google Scholar | PubMed |
37 Sheel M, Vun Voo T, Pingault N, Sloan-Gardner TS, Marmor A, Kirk MD, Johnston V, Coleman K. Vaccine breakthrough infections in a highly-vaccinated Australian population during a SARS-CoV-2 Delta outbreak. Commun Dis Intell (2018) 2022; 46:.
| Crossref | Google Scholar | PubMed |
39 Stock P. COVID-19 schools data reveal: Unreleased Victorian data and analysis on masks, RATs and cases. Cosmos Magazine, 22 February 2023. Available at https://cosmosmagazine.com/health/covid-19-schools-data-reveal-unreleased-victorian-data-and-analysis-on-masks-rats-and-cases/ [cited 23 May 2025].
40 National Centre for Immunisation Research and Surveillance. Paediatric SARS-CoV-2 serosurvey 2022, Australia Summary report, 3 November 2022. NCIRS; 2022. Available at https://ncirs.org.au/sites/default/files/2022-11/PAEDS%20NCIRS_COVID-19%20Paediatric%20Serosurvey%202022%20Report_3-11-2022_Final_1.pdf [cited 23 May 2025].
